IP Library Granted Patent US 9,108,923
Granted Patent B2
US 9,108,923 · App. 13/946,959 · Granted Aug 18, 2015

Compounds, compositions, and methods for cancer therapy

Inventors: Drew Adams (Cambridge, MA); Mingji Dai (West Lafayette, IN); Stuart Schreiber (Boston, MA); Mahmud Mustaqim Hussain (Cambridge, MA); Zarko Boskovic (Cambridge, MA)
Assignees: Howard Hughes Medical Institute; The Broad Institute; The President and Fellows of Harvard College
C07D211/86A61K31/4015A61K31/444A61K31/4412A61K31/4436A61K31/45A61K31/55A61K45/06C07C233/91C07D207/38C07D211/74C07D223/10C07D225/02C07D401/04C07D405/06C07D409/04C07D409/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,108,923
App. No.
13/946,959
Granted
Aug 18, 2015
Kind
B2
Abstract

Compounds including various oligomers of piperlongumine and/or piperlongumine analogues as well as certain piperlongumine analogues that exhibit improved toxicity to cancer cells are disclosed. Also provided are compositions that comprise the compounds, methods of making compositions comprising the compounds, methods of making the compounds, and the use of compounds in methods for treating cancer.

Claims (39)

1. A compound having the formula:

wherein A is C(O) or S(O) 2 ;

wherein B is alkenyl or alkynyl;

wherein n=0, 1, 2, or 3;

wherein R 1 is selected from the group consisting of a hydrogen, C≡C-alkyl, C≡C-cycloalkyl, C≡C-cycloalkyl halide, C≡C-phenyl, C≡C-thienyl, and a C≡C-phenyl halide wherein the halide is substituted ortho to the phenyl ring carbon that is bound to the alkynyl carbon;

wherein R 2 is selected from the group consisting of hydrogen, alkyl, alkenyl, and an aryl group;

wherein R 3 is selected from the group consisting of hydrogen, alkyl, alkenyl, and an aryl group; and,

wherein R 4 is selected from the group consisting of:

(i) substituted phenyl when B is alkynyl and R 1 is hydrogen,

(ii) a moiety of the formula:

 wherein, R 5 is selected from the group consisting of hydrogen, halogen, and methoxy, and wherein each of R 6 , R 7 , and R 8 are independently selected from the group consisting of hydrogen, bromine, chlorine, fluorine, keto, hydroxyl, alkyl, alkenyl, alkoxy, an aminoalkenyl, and an aminoalkoxy group with the proviso that R4 is (III) only when R1 is not hydrogen,

(iii) a moiety of the formula:

 and

(iv) a moiety of the formula (V):

 wherein A is C(O) or S(O) 2 , wherein X, when present in (V), is an alkenyl, aryl, or combination thereof;

wherein n=0, 1, 2, or 3;

wherein R 9 is selected from the group consisting of a hydrogen, C≡C-alkyl, C≡C-cycloalkyl, C≡C-cycloalkyl halide, C≡C-phenyl, C≡C-thienyl, and a C≡C-phenyl halide wherein the halide is substituted ortho to the phenyl ring carbon that is bound to the alkynyl carbon;

wherein R 10 is selected from the group consisting of hydrogen, alkyl, alkenyl, and an aryl group; and,

wherein R 11 is selected from the group consisting of hydrogen, alkyl, alkenyl, and an aryl group.

2. The compound of claim 1 ,

wherein R4 is selected from the group consisting of a moiety of the formula:

and a moiety of the formula:

wherein A is C(O) or S(O) 2 ,

wherein X, when present in (V), is an alkyl, alkenyl, alkynyl, aryl, or combination thereof;

wherein n=0, 1, 2, or 3;

wherein R 9 is selected from the group consisting of a hydrogen, C≡C-alkyl, C≡C-cycloalkyl, C≡C-cycloalkyl halide, C≡C-phenyl, C≡C-thienyl, and a C≡C-phenyl halide wherein the halide is substituted ortho to the phenyl ring carbon that is bound to the alkynyl carbon;

wherein R 10 is selected from the group consisting of hydrogen, alkyl, alkenyl, and an aryl group; and,

wherein R 11 is selected from the group consisting of hydrogen, alkyl, alkenyl, and an aryl group.

3. The compound of claim 1 , wherein R 1 is a C≡C-cycloalkyl group wherein said cycloalkyl is a C3 to C6 ring and/or wherein R 3 is hydrogen or a thienyl group.

4. The compound of claim 3 , wherein R 1 is a C≡C-cycloalkyl, wherein said cycloalkyl is substituted at the ring carbon that is bound to the alkynyl carbon with a hydroxyl group and/or wherein R 3 is hydrogen or a thienyl group.

5. The compound of claim 1 , wherein R 1 is a C≡C-phenyl or a C≡C-phenyl halide wherein the halide is substituted ortho to the phenyl ring carbon that is bound to the alkynyl carbon and/or wherein R 3 is hydrogen or a thienyl group.

6. The compound of claim 2 , wherein R 1 and R 9 are independently selected from a group consisting of hydrogen, a halogen, and a C≡C-cycloalkyl group wherein said cycloalkyl is a C3 to C6 ring and/or wherein R 3 and R11 are independently selected from a group consisting of hydrogen and a thienyl group.

7. The compound of claim 6 , wherein R 1 and R 9 are independently selected from the group consisting of hydrogen, a halogen, and a C≡C-cycloalkyl group, wherein said cycloalkyl is substituted at the ring carbon that is bound to the alkynyl carbon with a hydroxyl group and/or wherein R 3 is hydrogen or a thienyl group.

8. The compound of claim 2 , wherein R 1 and R 9 are independently selected from the group consisting of hydrogen, a halogen, and is a C≡C-phenyl or a C≡C-phenyl halide wherein the halide is substituted ortho or para to the phenyl ring carbon that is bound to the alkynyl carbon and/or wherein R 3 is hydrogen or a thienyl group.

9. The compound of claim 1 , wherein said compound has a formula selected from the group consisting of:

10. A composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

11. The composition of claim 10 , wherein said composition further comprises an additional chemotherapeutic agent.

12. A method of treating cancer comprising administration of a therapeutically effective amount of the compostion of claim 10 to a subject in need thereof, wherein the cancer is a cancer of the lung or cervix.

13. The method of claim 12 , where said method further comprises administration of an additional chemotherapeutic agent.

Assignments (4)
CONFIRMATORY LICENSE Recorded May 19, 2015
From: BROAD INSTITUTE, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035731/0484 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2015
From: ADAMS, PH.D., DREW J.; HUSSAIN, PH.D., MAHMUD; BOSKOVIC, PH.D., ZARKO
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 035649/0660 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2015
From: SCHREIBER, STUART
To: THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE; THE BROAD INSTITUTE
Reel/Frame 035649/0773 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2015
From: DAI, MINGJI
To: THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 035649/0856 →
Continuity (3)
Provisional Application 61779434 · Mar 13, 2013
Provisional Application 61674100 · Jul 20, 2012
Related Publication 20140024639A1 · Jan 23, 2014